Upgrades, downgrades, and outlook changes from major analysts.
Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.
1,435 total articles
BofA Securities raised its price target for VF Corp. (VFC) to $15.00 from $14.00 while maintaining an Underperform rating. The firm boosted fiscal 2026 and 2027 EPS estimates following a third-quarter earnings beat, but its target remains below InvestingPro's Fair Value calculation. VF reported better-than-expected results for Q3 2026 and issued mo…
BofA Securities raised its price target on PPG Industries to $118 from $116 while retaining a Neutral rating, citing signs that the company is fostering an environment conducive to organic growth. The decision follows mixed fourth-quarter results that showed revenue and organic sales gains but an earnings-per-share miss and ongoing margin pressure …
BofA Securities raised its price target on C.H. Robinson Worldwide to $225 from $188 and kept a Buy rating after the logistics provider reported fourth-quarter 2025 adjusted EPS of $1.23, beating both BofA and consensus estimates. The bank singled out the company's use of agentic AI and productivity improvements as drivers of margin expansion and m…
BofA Securities trimmed its price target on AXIS Capital to $115 from $119 while leaving the stock at Neutral after the insurer posted fourth-quarter 2025 results that surpassed both BofA and consensus forecasts. The beat was attributed to lower catastrophe losses, favorable reserve development and a reduced quarter tax rate, but was partly offset …
BofA Securities raised its price target on Meta Platforms Inc. to $885 from $810 while maintaining a Buy rating. The upgrade reflects analyst Justin Post's view that Meta is extracting stronger returns from artificial intelligence compared with peers, is building a self-funded infrastructure platform, and is on track for positive free cash flow in …
Morgan Stanley raised its price target on IBM to $304 from $252 while keeping an Equalweight rating, citing stronger-than-expected free cash flow in 2025 and fourth-quarter outperformance driven by Enterprise License Agreement renewals and mainframe strength. IBM reported EPS of $4.52 and revenue of $19.7 billion for Q4 2025, beating consensus, and…
BMO Capital raised its price target on Houlihan Lokey (HLI) to $211 from $209 while keeping an Outperform rating, after the investment bank reported fiscal third-quarter 2026 results that exceeded analyst expectations. Adjusted EPS of $1.94 topped BMO's $1.86 estimate and consensus projections; revenue of $717 million also surpassed forecasts. BMO …
Canaccord Genuity lowered its price target for Tesla to $520 from $551 while retaining a Buy rating. The firm adjusted its valuation model, applying roughly a 46x multiple to a reduced 2028 non-GAAP EPS estimate of $11.30. Canaccord frames Tesla as a play on the convergence of AI, robotics and energy decarbonization and notes the company’s vertical…
BTIG maintained its Buy rating and $9,022 price target on NVR Inc. after the homebuilder reported fourth-quarter 2025 results that outpaced analyst forecasts. The company posted an EPS of $121.54, driven by higher homebuilding revenue and disciplined SG&A, while orders and absorption showed unexpected resilience. BTIG has raised its 2026 and 2027 E…
BTIG reaffirmed its Buy rating on Carvana and held a $535 price target despite heightened market scrutiny over the company's relationship with DriveTime. The broker disputes several technical claims underpinning recent allegations and highlights continued analyst support and positive price-target revisions from peers.
BMO Capital raised its price objective on C.H. Robinson to $180 from $160 while retaining a Market Perform stance. The logistics firm is trading near its 52-week high after strong one-year returns. Analysts point to productivity gains and segment-level volume growth, but valuation metrics and a revenue shortfall in the latest quarter keep expectati…
BMO Capital reduced its 12-month price target on ServiceNow to $170 from $175 while retaining an Outperform rating. The firm described the company's fourth quarter as "solid if unspectacular," noted subscription revenue guidance roughly in line with consensus for fiscal 2026 (excluding M&A), and highlighted 25% year-over-year monthly active user gr…
BMO Capital has reiterated an Outperform rating and a $120 price target on Disc Medicine (IRON), citing three pillars of confidence in the likelihood of regulatory approval for the company's lead candidate, bitopertin. The firm sees a meaningful upside from current prices and assigns a 60% probability of success, while other analysts also maintain …
BMO Capital increased its price target on GE Vernova (GEV) to $785 from $780 while keeping an Outperform rating, citing robust gas turbine bookings and service agreements that left the company with 83 gigawatts in commitments at year-end. The firm highlighted the company’s guidance increases for fiscal 2026 and 2028 tied to the forthcoming Prolec a…
BMO Capital reduced its Microsoft price target to $575 from $625 but kept an Outperform rating, citing Azure growth that fell short of investor expectations and higher cash capital expenditures that could constrain free cash flow. The firm nonetheless noted continued strength in commercial bookings and remaining performance obligations, and adjuste…
BMO Capital raised its 12-month price objective for IBM to $350 from $305 while retaining a Market Perform rating. The firm pointed to robust Data segment growth and free cash flow that offset weakness in Red Hat and Consulting, and described fiscal 2026 revenue guidance as in line with expectations and FCF guidance as above expectations.
The U.S. Food and Drug Administration has placed clinical holds on Regenxbio's investigational gene therapies RGX-111 and RGX-121, citing a neoplasm found in a pediatric patient treated with RGX-111 four years earlier. The announcement prompted a steep drop in the company's stock, raised questions around the timing of a priority review voucher and …
Evercore ISI raised its price target on Lam Research to $275 from $241 while retaining an Outperform rating, citing a stronger-than-expected outlook for wafer fabrication equipment (WFE) spending. Lam Research reported an earnings beat and raised guidance, and multiple other firms have increased their price targets following the results and guidanc…
Goldman Sachs has affirmed a Buy rating on Progressive Corporation with a $230 price target, reflecting about a 14% potential total return. The firm left its EPS projections for 2026-2028 mostly intact, but raised its 2026 Personal Auto policies-in-force growth forecast to 8.1% after strong quarterly growth. Goldman also made modest adjustments to …
Goldman Sachs has maintained a Sell rating on Halozyme Therapeutics with a $58 price target, a mark well below the current share price. The firm’s view reflects concerns about royalty revenue durability beyond 2029, even as Halozyme reported robust near-term growth, raised multi-year revenue guidance and disclosed strategic acquisitions and partner…
Evercore ISI raised its price objective on IBM to $345 from $330 and reaffirmed an Outperform rating after the company's December quarter report. IBM topped revenue and EPS estimates, showed broad-based segment growth, and provided 2026 guidance that Evercore called "fairly conservative." The firm highlighted multiple catalysts that could push resu…
Jefferies has maintained a Buy rating on ServiceNow (NOW) with a $175 price target, pointing to robust subscription revenue and high gross margins. The stock, trading near its 52-week low, reported Q4 2025 results that beat consensus on both revenue and EPS. RBC Capital trimmed its price target but kept an Outperform rating amid mixed investor sent…
Goldman Sachs reduced its 12-month price target for Las Vegas Sands to $73 from $80 while retaining a Buy rating, citing divergent performance across the operator's regional businesses. Singapore outperformed expectations, but Macau fell short of estimates and saw margin pressure. The company also reported a quarterly earnings and revenue beat for …
Microsoft reported quarterly results that topped estimates for revenue, non-GAAP earnings per share, and operating margins, and logged strong year-over-year revenue growth on a trailing 12-month basis. Despite these outcomes and signals of improving margin discipline amid elevated AI infrastructure costs, the stock fell about 6% in after-hours trad…
RBC Capital has increased its price objective on Lam Research to $290 from $260 and reaffirmed an Outperform rating after the company reported a strong December 2025 quarter. The firm raised earnings estimates, citing healthy wafer fabrication equipment demand, market-share gains and management guidance calling for roughly 23% WFE growth in 2026. M…
